[ 3 ] Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty five years’experience of prophylactic treatment in severe haemophilia A and B[J]. J Intern Med, 1992, 232(1): 25-32.
[4]
[ 4 ] Berntorp E, Astermark J, Bjorkman S, et al. Concensus perspectives on prophylactic therapy for hecmophilia: summary statement[J]. Haemophilia, 2003, 9(Suppl 1): 1-4．
[5]
[ 5 ] Berntorp E, Boulyjenkow V ,Berttler D, et al. Modern treatment of haemophilia[J]. Bull world Health Orsan,1995, 73(5): 691-701．
[6]
[ 6 ] National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations and concerning prophylaxis[M]．New York: National Hemophilia Foundation. 1994: 197.
[7]
[ 7 ] Fisher K. The effects of postponing prophylaxisctic treatment on long-term outcome in patients with severe hemophilia[J]. Blood, 2002, 99(7): 2337-2341．
[8]
[ 8 ] Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia[J]. Semin Thrombo Hemost, 2003, 29(6): 585-594．
Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcoraes for severe factor VIII-deftcient haemophiliacs[J]. J Intern Med, 1994, 236(4): 391-394.
[11]
Kreuz W, Escuriola Ettingshausen C, Funk M, et al. Prevention of joint damage in hemophilic children with early prophylaxis[J]. Orthopade, 1999, 28(4): 341-346．
[12]
Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for Severe haemophilia: a comparison of coeta and long-term outcome[J]. Haemophilia, 2002, 8(6): 745-752．
[13]
Feldman BM，Pai M，Rivard GE，et al. Tailored prophylaxis In severe hemophilia A: interim result from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study[J]. J Thremb Haemost, 2006, 4(6): 1228-1236．
[14]
Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A[J]. Haemophilia, 2008, 14(4): 743-752．
[15]
ter Avest PC, Fischer K, Mancuso ME, et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice[J]. J Thromb Hanmost, 2008, 6(12): 2048-2054．
[16]
Bafimno V, Santacroce R, Chetta M, et al. Polymorphisms in genes involved in autoimmune disease and the risk of FVⅢ inhibitor development in Italian patients with haemophilia A[J]. Haemophilia, 2010, 16(3): 469-473.
[17]
Morado M, Villar A, Jimtnez Yuste V, et al. Prophylactic treatment effects on inhibitor risk：experience in one centre[J]．Haemophilia, 2005, 11(2): 79-83．
[18]
Ragni MV, Ojeifo O, Feng J, et al. Risk factors for inhibitor formation in hemophilia: a prevalent case-control study[J]. Haemophilia, 2009, 15(5): 1074-1082．
[19]
Ahstrom J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing，coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia[J]. Haemophilia, 2004, 10(6): 689-697．
[20]
Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia[J]. Expert Opin Emerg Drugs, 2010, 15(4): 597-613.
[21]
Turecek P, Scheifflinger F, Siekmann J, et al. Biochemical and functional characterization of PEGylated rVWF[J]. Blood, 2006, 108(11): 1021.
[22]
Turecek P, Siekmann J, Gritsch H, et al. In vitro and in vivo characterization of full-length rFVIII modified with PEG via coupling to primary amino groups[J]. Blood, 2007, 110(11): 3147.
[23]
Rottensteiner H, Turecek PL, Pendu R, et al. PEGylation or polysialylation reduces FⅧ binding to LRP resulting in prolonged half-life in murine models[J]. Blood, 2007, 110(11): 3150.
[24]
Van Cott KE, Monahan PE, Nichols TC, et al. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide[J]. Haemophilia, 2004, 10(Suppl 4): 70-76.
[25]
Kumaran V, Benten D, Follenzi A, et al. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice[J]. J Thromb Haemost, 2005, 3(9): 2022-2031.
[26]
Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice[J]. J Clin Invest, 2008, 118(3): 935-945.
[27]
Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FⅦa[J]. Blood, 2009, 113(16): 3682-3689.
[28]
Mátrai J, Chuah MK, VandenDriessche T. Preclinical and clinical progress in hemophilia gene therapy[J]. Curr Opin Hematol, 2010, 17(5): 387-92.
[29]
Powell JS, Ragni MV, White GC II, et al. Phase 1 trial of FⅧgene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion[J]. Blood, 2003, 102(6): 2038-2045.
